Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446736 | 0.88 | RAB9A (0.48) | F10KDM4E | |
| SCHEMBL4444789 | 0.86 | F10 (0.45) | F10MAPT | |
| SCHEMBL4449707 | 0.85 | F10 (0.59) | F10 | |
| SCHEMBL4450073 | 0.84 | F10 (0.41) | F10 | |
| SCHEMBL76341 | 0.80 | F10 (0.56) | F10 | |
| SCHEMBL76342 | 0.80 | F10 (0.56) | F10 | |
| SCHEMBL5428908 | 0.79 | F10 (0.60) | F10 | |
| SCHEMBL76208 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL76209 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL4444868 | 0.76 | F10 (0.54) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557102-B2 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2009-07-07 | — | — | US | claimed |
| EP-1608645-B1 | PYRAZOLIDINE-1,2-DICARBOXYLDIPHENYLAMIDE DERIVATIVES AS COAGULATION FACTOR XA INHIBITORS FOR THE TREATMENT OF THROMBOSES | MERCK PATENT GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
| US-20060183742-A1 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-7557102-B2 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2009-07-07 | — | — | US | disclosed |
| US-20060183742-A1 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183742-A1 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses | F2, SERPINC1, F12 | F10 7/4885TAS1R3 594/4885TAS1R1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.